Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗

June 16, 2025

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Via Benzinga

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗

June 16, 2025

The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.

Via Investor's Business Daily

Topics ETFs

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

June 16, 2025

From Halper Sadeh LLC

Via Business Wire

Monday's pre-market session: top gainers and losers ↗

June 16, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

What to Expect from Sage Therapeutics's Earnings ↗

April 28, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts ↗

February 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

June 16, 2025

From Ademi & Fruchter LLP

Via Business Wire

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

June 16, 2025

From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.

Via GlobeNewswire

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

April 29, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts ↗

April 25, 2025

Via Benzinga

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

April 15, 2025

From Sage Therapeutics, Inc.

Via Business Wire

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE

April 11, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert ↗

March 27, 2025

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming...

Via Benzinga

Topics Supply Chain World Trade

KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 25, 2025

Via Benzinga

Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

March 25, 2025

Via Benzinga

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

March 17, 2025

From Grabar Law Office

Via GlobeNewswire

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE

March 17, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your

March 14, 2025

From Grabar Law Office

Via GlobeNewswire

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

March 13, 2025

From Grabar Law Office

Via GlobeNewswire

Long-Term Shareholder Notice: Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

March 12, 2025

From Grabar Law Office

Via GlobeNewswire

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as

March 10, 2025

From Grabar Law Office

Via GlobeNewswire

Sage Therapeutics Announces R&D Leadership Transition

March 04, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

February 11, 2025

From Sage Therapeutics, Inc.

Via Business Wire

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? ↗

February 11, 2025

Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.

Via Benzinga

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok ↗

January 31, 2025

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Via Benzinga

Earnings Scheduled For February 11, 2025 ↗

February 11, 2025

Via Benzinga

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

January 28, 2025

From Sage Therapeutics, Inc.

Via Business Wire

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail ↗

January 27, 2025

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.